A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
Recruiting
Observational Study
Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 21 – 99
- Sex
- Any
- Study type
- Observational
- Participants needed
- 600 (estimated)
- Sponsor
- National Cancer Centre, Singapore · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
There are limited in depth studies on the epidemiology and clinical management of EGFR exon 20 insertion mutated NSCLC in Asia. In addition, there is preliminary data suggesting the exact location of the insertion and variant may influence the response and efficacy to novel EGFR targeted therapies.
This study aims to fill this knowledge gap, by comprehensively characterising the epidemiology and …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Histologically confirmed advanced NSCLC
2. Positive testing result from any locally approved test (including but not limited to RT-PCR, Cobas and NGS) for EGFR exon 20 insertion mutation
3. Diagnosis date from 1 Jan 2013 to 31 Dec 2024 (to allow for minimum 12 months of follo…
Contacts